Evidence map›Paper›PMID 29532488›Full record

ArticleTransfusion2018

Clinical-scale production of cGMP compliant CD3/CD19 cell-depleted NK cells in the evolution of NK cell immunotherapy at a single institution.

Shelly M Williams, Darin Sumstad, Diane Kadidlo, Julie Curtsinger, Xianghua Luo, Jeffrey S Miller, David H McKenna

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Natural Killer Cell Mechanosensing in Solid Tumors.Bioengineering (Basel, Switzerland) · 2024
    Review
  8. Review
  9. Review
  10. Review
  11. Advances in NK cell production.Cellular & molecular immunology · 2022
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. NK cells for cancer immunotherapy.Nature reviews. Drug discovery · 2020
    Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Shelly M WilliamsDepartment of Laboratory Medicine and Pathology, University of Minnesota, Saint Paul, Minnesota.
Darin SumstadMolecular and Cellular Therapeutics, University of Minnesota, Saint Paul, Minnesota.
Diane KadidloMolecular and Cellular Therapeutics, University of Minnesota, Saint Paul, Minnesota.
Julie CurtsingerMasonic Cancer Center, University of Minnesota, Saint Paul, Minnesota.
Xianghua LuoMasonic Cancer Center, University of Minnesota, Saint Paul, Minnesota.
Jeffrey S MillerMasonic Cancer Center, University of Minnesota, Saint Paul, Minnesota.
David H McKennaDepartment of Laboratory Medicine and Pathology, University of Minnesota, Saint Paul, Minnesota.
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Jeffrey S. Miller · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI FELICES, MARTIN · 2005 to 2025
$38.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Integrated training in development and clinical practice of cell-based therapiesR25HL128372 · NHLBI · UNIVERSITY OF MINNESOTA · PI HUBEL, ALLISON, MCKENNA, DAVID HURLEY · 2015 to 2019
$553k
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA111412NCI NIH HHS P30 CA077598NHLBI NIH HHS HHSN268201000008CNHLBI NIH HHS R25 HL128372
6 · The paper itself

Abstract

backgroundAllogeneic natural killer (NK) cell adoptive immunotherapy is a growing therapeutic option for patients. Clinical-scale production of NK cells using immunomagnetic selection complies with current good manufacturing practices (cGMPs) and allows for closed-system, automated purification. We report our experience with CD3/CD19 cell-depleted (CD3/CD19 STUDY DESIGN AND

methodsNonmobilized mononuclear cells collected by apheresis were incubated with anti-CD3/anti-CD19 microbeads and depleted in an automated cell selection system (CliniMACS, Miltenyi). The NK cell-enriched products were incubated overnight in interleukin (IL)-2 or IL-15, washed, and resuspended prior to lot release testing and infusion.

resultsSince 2010, 94 freshly infusible CD3/CD19

conclusionClinical-scale/cGMP production of NK cells using CD3/CD19 cell-depletion effectively minimized T-cell and B-cell contamination in a single manipulation without compromise to NK-cell recovery. Cytokine activation increased in vitro cytotoxicity compared to column-depleted, preactivated NK cells.

Indexed as

Antigens, CD19CD3 ComplexCell Culture TechniquesCytokinesCytotoxicity, ImmunologicHumansImmunomagnetic SeparationImmunotherapyKiller Cells, NaturalLeukapheresisLymphocyte DepletionAntigens, CD19CD3 ComplexCytokines

Identifiers

PMID29532488
PMCPMC6021208
OpenAlexW2789437216

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.